Presenting Pivotal Phase 3 Sickle Cell Data at EHA 2026- Agios Pharmaceuticals
Agios Pharmaceuticals shared a post on LinkedIn:
“Agios News: Today, during the Plenary Abstracts Session at EHA 2026, we presented detailed results from the Rise up Phase 3 trial – the first pivotal trial to validate pyruvate kinase (PK) activation as a new treatment approach in Sickle Cell Disease.
This oral presentation included new transfusion burden and hemoglobin responder analyses that reinforce the strong anti-hemolytic profile of our first-in-class PK activator.
Read the results.”
Mohamed A., Franchise Director, Blood Disorders, Rare Disease GCC at NewBridge Pharmaceuticals, shared this post on LinkedIn:
“Results from the Rise up Phase 3 trial – the first pivotal trial to validate pyruvate kinase (PK) activation as a new treatment approach in Sickle Cell Disease.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Nov 4, 2026, 18:57Connecting Haemophilia Centres, Certifying Treaters, and Improving National Data in Romania – EHC
-
Nov 4, 2026, 18:45Smitirupa Mishra: A Practical Guide to Coagulation Pathway Assessment and Laboratory Interpretation
-
Nov 4, 2026, 15:59Alessandra Bosch: A Successful Patient Day for the Bleeding Disorders Community in Zürich
-
Nov 4, 2026, 15:47Wolfgang Miesbach: Targeting Hepatic Endothelial Cells for Lentiviral Gene Therapy in Haemophilia A
-
Nov 4, 2026, 15:20Augustina Isioma Ikusemoro: Before You Transfuse, Think PBM
-
Nov 4, 2026, 14:23Advancing Hemophilia Care Through Global Research – WFH
-
Nov 4, 2026, 14:12Jean-Jacques Kiladjian: From JAK Inhibitor-Associated Skin Cancers to Laboratory Discovery
-
Nov 4, 2026, 13:59Rita Li: ASH 2026 Abstract Achievement Award for Gut Microbiome Research
-
Nov 4, 2026, 13:38Omid Seidizadeh: Improving Access to von Willebrand Disease Diagnosis and Treatment Across Europe